Active Recombinant Human ERBB3 Protein (Ser20-Gly538), C-6×His tagged

• Cat.No.: ERBB3-28H
• Product Overview: Recombinant human ERBB3 protein (Ser20-Gly538) with 6×His tag at C-terminus was expressed in Human embryonic kidney cell, HEK293.

Specification

• Description: This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized.
• Source: HEK293
• Species: Human
• Tag: His
• Bio-activity: Measured by its ability to inhibit the biological activity of Neuregulin-1-beta 1 on MCF-7 human breast cancer cells. The ED50 for this effect is 0.3-3 μg/mL in the presence of 10 ng/mL Recombinant Human NRG1-beta 1/HRG1-beta 1 Extracellular Domain.
• Molecular Mass: Predicted Molecular Mass: 56.9 kDa
  SDS-PAGE: 70-75 kDa, reducing conditions
• Protein length: Ser20-Gly538
• N-terminal Sequence Analysis: Ser20
• Endotoxin: < 1.0 EU/μg of the protein by the LAL method.
• Purity: > 95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 centigrade as supplied.
  1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
  3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
• Storage Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Reconstitution: Reconstitute at 500 μg/mL in PBS.
• Shipping: The product is shipped at ambient temperature.

Gene Information

• Gene Name: ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) [ Homo sapiens (human) ]
• Official Symbol: ERBB3
• Synonyms: ERBB3; v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); LCCS2, lethal congenital contracture syndrome 2; receptor tyrosine-protein kinase erbB-3; HER3; proto-oncogene-like protein c-ErbB-3; tyrosine kinase-type cell surface receptor HER3; LCCS2; ErbB-3; c-erbB3; erbB3-S; MDA-BF-1; c-erbB-3; p180-ErbB3; p45-sErbB3; p85-sErbB3; MGC88033
• Gene ID: 2065
• mRNA Refseq: NM_001005915
• Protein Refseq: NP_001005915
• MIM: 190151
• UniProt ID: P21860

Reviews

10/28/2021

Their expert team has been instrumental in addressing any challenges or concerns I have encountered during my experiments.

08/11/2021

Their prompt and comprehensive assistance has proven invaluable in overcoming obstacles and optimizing my experimental protocols.

03/03/2020

The ERBB3 protein boasts remarkable stability, allowing for extended storage without compromising its integrity or performance.

Q&As

What are the potential side effects of targeting ERBB3 in cancer therapy?

Potential side effects may include skin rash, diarrhea, and cardiovascular issues, as seen with other drugs targeting the EGFR family.

How does ERBB3 contribute to resistance to certain cancer therapies?

ERBB3 activation has been associated with resistance to some targeted therapies, such as EGFR inhibitors, making it a challenging target in cancer treatment.

How does ERBB3 interact with other receptors in the EGFR family?

ERBB3 can form heterodimers with other EGFR family members, such as EGFR and HER2, leading to the activation of downstream signaling pathways.

Can ERBB3 be used as a biomarker for prognosis in cancer patients?

Yes, elevated ERBB3 expression has been linked to poor prognosis in certain cancers, serving as a potential biomarker for patient outcomes.

In which types of cancers is ERBB3 commonly overexpressed?

ERBB3 overexpression is frequently observed in breast, ovarian, and gastric cancers, among others.